On the issue of the safety of prescribing antipsychotics after suffering a malignant neuroleptic syndrome in the treatment of patients with schizophrenia
Suggested citation:
Malin DI, Zaycev DA. [On the issue of the safety of prescribing antipsychotics after suffering a malignant neuroleptic syndrome in the treatment of patients with schizophrenia]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2019;(2):49-53. Russian
This article is devoted to analysis of a clinical case of a female patient with a prolonged course of paranoid schizophrenia, who had developed the neuroleptic malignant syndrome while receiving the atypical antipsychotics treatment (initially – risperidone, then – clozapine). We deliberate the tactics of providing treatment for schizophrenia with complications in the form of the neuroleptic malignant syndrome, and the problem of whether it is safe to reissue the prescription of antipsychotics, taking into account the secondary prevention of complications.
Keywords neuroleptic malignant syndrome; schizophrenia; antipsychotic therapy; electroconvulsive therapy
1. Kekelidze ZI. Chehonin VP. Kriticheskie sostojanija v psihiatrii . Moscow; 1997. 362 p. Russian. 2. Cygankov BD. Kliniko-patogeneticheskie zakonomernosti razvitija febril'nyh pristupov shizofreni i sistema ih terapii . Moscow; 1997. 232 p. Russian. 3. Malin DI, Ravilov RS. Prevalence, clinical picture, diagnosis and treatment of severe complications of neuroleptic therapy. Sotsial'naya i klinicheskaya psikhiatriya [Social and Clinical Psychiatry]. 2014;24(4):90-7. Russian. 4. Malin D. [Neuroleptic Malignant Syndrome: diagnosis and treatment]. Sovremennaya terapiya psikhicheskikh rasstroystv [Contemporary Therapy of Mental Disorders]. 2016;(2):2-9. Russian. 5. American Psychiatric Association. Diagnostic and Statistical manual of mental disorders. 5th ed. Washington, USA, DC: American Psychiatric Association; 2012-2013. 947 p. ISBN 6. Spivak B, Malin D, Kozirev V, et al. Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow. Eur. Psychiatry. 2000; 15:330- 3. 7. ChehoninVP, Morozov GV, MorkovkinVM, KekelidzeZI. Immunohimicheskoe izuchenie pronicaemosti gematojencefalicheskogo bar'era pri kriticheskih sostojanijah, obuslovlennyh febril'noj shizofreniej i ostrymi alkogol'nymi jencefalopatijami. Mat. 8 s"ezda nevropat. i psihiatr. Moscow; 1988; 3. p. 132-4. Russian. 8. Malin D. Pobochnoe dejstvie psihotropnyh sredstv. Moscow; Vuzovskaja kniga. 2000. 207p. Russian. 9. Caroff SN. Theneurolepticmalignant syndrome. J Clin Psychiat. 1980; 41(3):1-26. 10. Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164:870–6. 11. Keck PE, Pope HG, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry.1989; 46:914–8. 12. Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust NZ J Psychiatry.1999; 33:650–9. 13. Patel AL, Shaikh WA, Khobragade AK, et al. Electroconvulsive Therapy in Drug Resistant Neuroleptic Malignant Syndrome. JAPI. 2008; 56: 49-50. 14. Reulbach U, Dutsch C, Biermann T, et al. Managing an effective treatment for neuroleptic malignant syndrome. Critical Care. 2007; 11: 4-10. 15. Moscovich M, Novak F, Fernandes A, et al. Neuroleptic malignant syndrome. Arq Neuropsiquiatr. 2011; 69(5): 751-5. 16. Manu P, Sarpal D, Muir O, et al. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res. 2011; 134:180–6.
DOI: http://dx.doi.org/10.24411/1560-957X-2019-11920
Article Metrics
Metrics powered by PLOS ALM